Introducing the AirFit F40
Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask - Seite 2
AirFit F40 masks are available in the U.S., with plans to launch in Canada, followed by EMEA, Latin America, and APAC. For more information, visit ResMed.com/AirFitF40.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health
technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the
professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we help improve quality of life, reduce the impact of chronic
disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For
media
+1
858.289.7272
news@resmed.com
For investors
+1 858.836.5000
investorrelations@resmed.com
1, 3 ResMed external clinical studies of current PAP users with ≥ 12 months’ therapy with either ResMed or competitor masks and who met 90-day compliance in the three months prior to the study. All participants used the ResMed AirFitF40 and a competitor mask for up to seven nights each at randomized order. Studies conducted in the U.S., October 4 -November 20, 2023. n=57.
Lesen Sie auch
2 Compliance is defined by the CMS as certain number of hours per night, and number of nights of use within first 90 days.